H
Henning Zeidler
Researcher at Leibniz University of Hanover
Publications - 4
Citations - 334
Henning Zeidler is an academic researcher from Leibniz University of Hanover. The author has contributed to research in topics: Infliximab & BASDAI. The author has an hindex of 3, co-authored 4 publications receiving 314 citations.
Papers
More filters
Journal ArticleDOI
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.
Xenofon Baraliakos,Joachim Listing,J Brandt,Angela Zink,Rieke Alten,Gerd R Burmester,E Gromnica-Ihle,Herbert Kellner,Matthias Schneider,H. Sörensen,Henning Zeidler,Martin Rudwaleit,Joachim Sieper,Juergen Braun +13 more
TL;DR: Discontinuation of long-term therapy with infliximab eventually led to relapse of disease activity in all patients but one and patients who were in partial remission according to the ASAS criteria and those with normal C-reactive protein levels at the time point of withdrawal had longer times to relapse after discontinuation of the treatment.
Journal ArticleDOI
Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease.
TL;DR: There was evidence that meloxicam was prescribed preferentially to patients who had not responded to NSAIDs previously, who had previously experienced NSAID-induced side effects (and so were at high risk for developing NSAid-induced GI toxicity), or who were more seriously impaired.
Journal ArticleDOI
Prescription and tolerability of meloxicam in day-to-day practice: postmarketing observational cohort study of 13,307 patients in Germany.
Henning Zeidler,Joachim P. Kaltwasser,Joachim P. Leonard,Thomas Kohlmann,Ralf Sigmund,Frank Degner,Marceline Hettich +6 more
TL;DR: Treatment with the selective cyclooxygenase-2 (COX-2) inhibitor meloxicam in doses of 7.5 mg and 15 mg resulted in meaningful treatment responses under real life conditions, despite inclusion of a substantial number of patients with insufficient effectiveness of previous use of non–COX–2 selective NSAIDs.
Proceedings ArticleDOI
OP0063 Three months results of a double-blind placebo controlled, phase-iii clinical trial of infliximab in active ankylosing spondylitis
J. Brandt,Rieke Alten,Gerd-Rüdiger Burmester,E Gromnica-Ihle,Herbert Kellner,Matthias Schneider,H Sörensen,Henning Zeidler,W Thriene,Joachim Sieper,J. Braun +10 more
TL;DR: A placebo-controlled trial to prove that the administration of infliximab has a beneficial effect on the short and long term course of severe AS, with impressive results in some of the patients.